- Earnings week ahead: BABA, CSCO, PLUG, AMAT, JD, and more
May 10, 2026
[Rolled newspaper with the headline Quarterly Results]
Zerbor
As earnings season enters another busy stretch, the upcoming week will bring a diverse mix of reports spanning AI infrastructure, semiconductors, e-commerce, clean energy, crypto, healthcare, and industrial technology.
In technology and AI, investors will closely watch results from Alibaba Group Holding Limited (BABA [https://seekingalpha.com/symbol/BABA]), Cisco Systems (CSCO [https://seekingalpha.com/symbol/CSCO]), Applied Materials (AMAT [https://seekingalpha.com/symbol/AMAT]), Nebius Group (NBIS [https://seekingalpha.com/symbol/NBIS]), Figma (FIG [https://seekingalpha.com/symbol/FIG]), Wix.com (WIX [https://seekingalpha.com/symbol/WIX]), monday.com (MNDY [https://seekingalpha.com/symbol/MNDY]), and quantum-focused names including Rigetti Computing (RGTI [https://seekingalpha.com/symbol/RGTI]), D-Wave Quantum (QBTS [https://seekingalpha.com/symbol/QBTS]), and Quantum Computing (QUBT [https://seekingalpha.com/symbol/QUBT]) for signals around enterprise spending, cloud demand, and the evolving AI ecosystem.
China and emerging-market consumer and fintech trends will also remain in focus through earnings from JD.com (JD [https://seekingalpha.com/symbol/JD]), Sea Limited (SE [https://seekingalpha.com/symbol/SE]), Nu Holdings (NU [https://seekingalpha.com/symbol/NU]), and StoneCo (STNE [https://seekingalpha.com/symbol/STNE]), while digital asset and crypto-market attention may center on Circle Internet Group (CRCL [https://seekingalpha.com/symbol/CRCL]), MARA Holdings (MARA [https://seekingalpha.com/symbol/MARA]), and CleanSpark (CLSK [https://seekingalpha.com/symbol/CLSK]).
Energy, mining, and commodity players such as Constellation Energy (CEG [https://seekingalpha.com/symbol/CEG]), Barrick Mining (B [https://seekingalpha.com/symbol/B]), Franco-Nevada (FNV [https://seekingalpha.com/symbol/FNV]), First Majestic Silver (AG [https://seekingalpha.com/symbol/AG]), Mosaic (MOS [https://seekingalpha.com/symbol/MOS]), Ovintiv (OVV [https://seekingalpha.com/symbol/OVV]), Lithium Argentina (LAR [https://seekingalpha.com/symbol/LAR]), and Canadian Solar (CSIQ [https://seekingalpha.com/symbol/CSIQ]) are expected to provide insight into commodity demand, energy markets, and the transition toward cleaner power infrastructure.
Speculative growth and next-generation mobility names including Archer Aviation (ACHR [https://seekingalpha.com/symbol/ACHR]), AST SpaceMobile (ASTS [https://seekingalpha.com/symbol/ASTS]), Virgin Galactic (SPCE [https://seekingalpha.com/symbol/SPCE]), Intuitive Machines (LUNR [https://seekingalpha.com/symbol/LUNR]), Plug Power (PLUG [https://seekingalpha.com/symbol/PLUG]), Blink Charging (BLNK [https://seekingalpha.com/symbol/BLNK]), and Eos Energy Enterprises (EOSE [https://seekingalpha.com/symbol/EOSE]) will offer another read on investor appetite for emerging technologies and long-duration innovation themes.
Meanwhile, healthcare, industrial, infrastructure, and consumer-facing companies such as Hims & Hers Health (HIMS [https://seekingalpha.com/symbol/HIMS]), Halozyme Therapeutics (HALO [https://seekingalpha.com/symbol/HALO]), Siemens Aktiengesellschaft (SIEGY [https://seekingalpha.com/symbol/SIEGY]), Simon Property Group (SPG [https://seekingalpha.com/symbol/SPG]), Under Armour (UAA [https://seekingalpha.com/symbol/UAA]), GoPro (GPRO [https://seekingalpha.com/symbol/GPRO]), and Manulife Financial Corporation (MFC [https://seekingalpha.com/symbol/MFC]) add further breadth across healthcare, manufacturing, consumer, and financial services markets.
With a reporting lineup that spans established global leaders and high-volatility growth names, the week ahead could provide fresh insight into risk appetite, AI monetization, consumer resilience, and the broader direction of global markets heading into the next phase of earnings season.
Below is a rundown of major quarterly updates anticipated for the week of May 11 to May 15:
MONDAY, MAY 11
PLUG POWER (PLUG [https://seekingalpha.com/symbol/PLUG])
Plug Power (PLUG [https://seekingalpha.com/symbol/PLUG]) is set to report Q1 results on Monday after the close, with investors hoping it can extend the momentum from a much-improved Q4 2025.
In Q4, Plug posted its first positive gross margin in years at 2.4%, on revenue of $225.2M, up 17.6% Y/Y. Management also reiterated a long-term profitability roadmap, targeting positive EBITDAS in Q4 2026, positive operating income by the end of 2027, and full profitability by the end of 2028.
Recent asset monetization, including a $132.5M sale to Stream Data Centers as part of a broader liquidity plan, has bolstered investor sentiment.
However, Wall Street is roughly Neutral while Seeking Alpha's Quant Rating System also remains cautious [https://seekingalpha.com/symbol/PLUG/ratings/quant-ratings], citing profitability and valuation.
SA contributor Henrik Alex reiterated a Sell view on Plug Power, arguing that the company’s margin improvement is encouraging but that cash burn remains high, the electrolyzer backlog is at multi-year lows, and management’s 2026 growth targets look difficult to achieve without a meaningful pickup in new orders.
* Consensus EPS Estimates: -$0.10
* Consensus Revenue Estimates: $139.76M
* Earnings Insight: Plug Power has missed EPS estimates in 8 consecutive reports, exceeding revenue forecasts in just 3 of those quarters.
ALSO REPORTING: Barrick Mining (B [https://seekingalpha.com/symbol/B]), Simon Property Group (SPG [https://seekingalpha.com/symbol/SPG]), Hims & Hers Health (HIMS [https://seekingalpha.com/symbol/HIMS]), 3D Systems Corporation (DDD [https://seekingalpha.com/symbol/DDD]), SeaDrill (SDRL [https://seekingalpha.com/symbol/SDRL]), Cronos Group (CRON [https://seekingalpha.com/symbol/CRON]), Marathon Digital Holdings (MARA [https://seekingalpha.com/symbol/MARA]), Blink Charging (BLNK [https://seekingalpha.com/symbol/BLNK]), GoPro (GPRO [https://seekingalpha.com/symbol/GPRO]), Mosaic (MOS [https://seekingalpha.com/symbol/MOS]), Uniti Group (UNIT [https://seekingalpha.com/symbol/UNIT]), Ovintiv (OVV [https://seekingalpha.com/symbol/OVV]), Danaos (DAC [https://seekingalpha.com/symbol/DAC]), ARKO Petroleum (APC [https://seekingalpha.com/symbol/APC]), Agenus (AGEN [https://seekingalpha.com/symbol/AGEN]), CleanSpark (CLSK [https://seekingalpha.com/symbol/CLSK]), Village Farms International (VFF [https://seekingalpha.com/symbol/VFF]), Circle Internet Group (CRCL [https://seekingalpha.com/symbol/CRCL]), and more.
TUESDAY, MAY 12
JD.COM (JD [https://seekingalpha.com/symbol/JD])
JD.com (JD [https://seekingalpha.com/symbol/JD]), one of China's largest e-commerce and supply chain technology platforms, is scheduled to report its Q1 results on Tuesday before the U.S. market opens, with investors closely watching whether the company can rebound from a challenging Q4.
JD.com's most recent quarter saw resilient full-year revenue growth, margin expansion, and a record user base, with strong performance in general merchandise and new businesses. However, the company posted its first quarterly loss in more than three years as the food-delivery subsidy war in China continued to take a toll on the e-commerce giant.
Looking ahead to Q1, management has expressed confidence in sustaining healthy growth across general merchandise, supermarket, fashion, and healthcare in 2026, while noting that electronics and home appliances are expected to recover only in the second half of the year due to a high base effect in H1. Food delivery investment is expected to decrease in 2026, with a renewed focus on healthy scaling and improved unit economics, a signal the market has been eager to hear following months of margin pressure from the bruising food delivery price war with rivals.
On the international front, JD.com has been expanding aggressively beyond China's borders. The company launched Joybuy, a shopping platform serving six European countries, including the U.K., in March 2026, while also making a $2.5B bid for German electronics retailer Ceconomy.
The company also completed a CNY10B senior notes offering in April 2026, signaling continued confidence in its capital position despite the near-term earnings headwinds.
Persistent US-China trade tensions and the ever-present risk of ADR delisting remain overhangs that keep a ceiling on valuation for many international investors, even as the underlying business continues to scale.
Wall Street sentiment remains broadly constructive, and Seeking Alpha's Quant rating system also suggests a Buy [https://seekingalpha.com/symbol/JD/ratings/quant-ratings].
SA author Byte Sized Alpha also recommends a Buy [https://seekingalpha.com/article/4897710-jdcom-logistics-ai-and-marketplace-growth-could-drive-a-re-rating] rating on JD.com (JD [https://seekingalpha.com/symbol/JD]), arguing that the stock remains undervalued as growth drivers across logistics, marketplace operations, advertising, and industrial AI systems continue to strengthen the long-term thesis.
The author highlights JD’s vertically integrated logistics network and international expansion through JoyExpress as key competitive advantages, while AI-driven tools such as JoyStreamer and JingYan Assistant are helping accelerate higher-margin advertising and marketplace revenue growth.
At roughly 10x forward earnings and around $30 per share, Byte Sized Alpha sees further upside potential, assigning a 12-month price target of $42.
* Consensus EPS Estimates: $0.53
* Consensus Revenue Estimates: $45.55B
* Earnings Insight: JD.com has topped EPS and revenue expectations in 7 of the past 8 quarters.
ALSO REPORTING: Sea Limited (SE [https://seekingalpha.com/symbol/SE]), Under Armour (UAA [https://seekingalpha.com/symbol/UAA]), First Majestic Silver (AG [https://seekingalpha.com/symbol/AG]), OrganiGram (OGI [https://seekingalpha.com/symbol/OGI]), GrowGeneration (GRWG [https://seekingalpha.com/symbol/GRWG]), Franco-Nevada (FNV [https://seekingalpha.com/symbol/FNV]), HUYA (HUYA [https://seekingalpha.com/symbol/HUYA]), B&G Foods (BGS [https://seekingalpha.com/symbol/BGS]), Zebra Technologies (ZBRA [https://seekingalpha.com/symbol/ZBRA]), Tencent Music Entertainment Group (TME [https://seekingalpha.com/symbol/TME]), Kopin (KOPN [https://seekingalpha.com/symbol/KOPN]), D-Wave Quantum (QBTS [https://seekingalpha.com/symbol/QBTS]), and more.
WEDNESDAY, MAY 13
CISCO SYSTEMS (CSCO [https://seekingalpha.com/symbol/CSCO])
Cisco Systems (CSCO [https://seekingalpha.com/symbol/CSCO]) is set to release its FQ3 results after Wednesday’s close, with expectations elevated after a run of strong quarters and bullish management commentary. The company has said it is positioned for its best fiscal year on record, driven by momentum in AI infrastructure and networking.
In its most recent quarter, Cisco beat expectations and raised its full-year outlook to revenue of $61.2B to $61.7B and non-GAAP EPS of $4.13 to $4.17, assuming current tariffs and exemptions remain in place through FY2026.
The AI infrastructure story remains the main driver heading into the print. Silicon One shipped its one millionth chip during Q2; Cisco unveiled the G300 architecture with 102.4 Tbps of switching bandwidth, and the company now has design wins with five of six major hyperscalers. A campus networking upgrade cycle and a sovereign cloud pipeline exceeding $2.5B add to the growth runway, and investors will be watching to see whether AI order momentum has stayed strong into Q3.
Splunk integration is the other major focus. Roughly two years after the deal closed, Cisco is still benefiting from cross-sell opportunities, but the cloud subscription transition continues to weigh on near-term recognized revenue. That said, the growth in Splunk’s ARR and product RPO supports the longer-term thesis, even if the monetization path remains gradual.
Margins will also be closely watched. Cisco is shifting from legacy networking hardware toward AI infrastructure leadership, but that mix shift is putting pressure on gross and operating margins. Management has guided Q3 non-GAAP gross margin of 65.5% to 66.5% and non-GAAP operating margin of 33.5% to 34.5%, while tariff exposure on memory, PCBs, and optics remains an added variable.
Wall Street remains broadly constructive with a Buy rating, but investors still appear to be weighing execution risk against the upside from AI and Splunk.
Meanwhile, Seeking Alpha's Quant Rating System suggests a Hold [https://seekingalpha.com/symbol/CSCO/ratings/quant-ratings].
* Consensus EPS Estimates: $1.04
* Consensus Revenue Estimates: $15.56B
* Earnings Insight: Cisco has beaten EPS and revenue estimates in 8 straight quarters.
ALSO REPORTING: Alibaba Group Holding (BABA [https://seekingalpha.com/symbol/BABA]), Nebius Group (NBIS [https://seekingalpha.com/symbol/NBIS]), Inovio Biomedical (INO [https://seekingalpha.com/symbol/INO]), Bionano Genomics (BNGO [https://seekingalpha.com/symbol/BNGO]), Paysafe Group Holdings (PSFE [https://seekingalpha.com/symbol/PSFE]), Manulife Financial (MFC [https://seekingalpha.com/symbol/MFC]), Wix.com (WIX [https://seekingalpha.com/symbol/WIX]), Capital Southwest (CSWC [https://seekingalpha.com/symbol/CSWC]), Energous (WATT [https://seekingalpha.com/symbol/WATT]), Shoulder Innovations (SI [https://seekingalpha.com/symbol/SI]), Dynatrace (DT [https://seekingalpha.com/symbol/DT]), Altimmune (ALT [https://seekingalpha.com/symbol/ALT]), Gilat Satellite Networks (GILT [https://seekingalpha.com/symbol/GILT]), COMPASS Pathways (CMPS [https://seekingalpha.com/symbol/CMPS]), Teekay (TK [https://seekingalpha.com/symbol/TK]), Doximity (DOCS [https://seekingalpha.com/symbol/DOCS]), Veru (VERU [https://seekingalpha.com/symbol/VERU]), and more.
THURSDAY, MAY 14
APPLIED MATERIALS (AMAT [https://seekingalpha.com/symbol/AMAT])
Applied Materials (AMAT [https://seekingalpha.com/symbol/AMAT]), the world’s largest semiconductor equipment maker by revenue, is set to report FQ2 results after Thursday’s close, with investors looking for another beat-and-raise quarter from one of the market’s key AI infrastructure beneficiaries.
In February, the company topped expectations in FQ1 results, while management said it expects its semiconductor equipment business to grow by more than 20% in calendar 2026. Applied then guided FQ2 revenue of about $7.65B and adjusted EPS of $2.64, and analysts have since edged estimates higher.
The biggest growth drivers remain gate-all-around transistors and high-bandwidth memory, where advanced tools are increasingly essential as chipmakers push to smaller nodes and more complex stacking. Applied’s $5B EPIC Center initiative is also a key focus, as investors watch for updates on customer co-development, commercialization timelines, and the pace of AI-related demand. China remains the main risk.
Management has already flagged a potential $600M FY2026 revenue headwind from tighter U.S. export restrictions, which could affect both tool shipments and service revenue.
The overall demand landscape driven by AI-related capital expenditures remains favorable, and Wall Street maintains a positive outlook ahead of the earnings report.
Meanwhile, Seeking Alpha's Quant Rating System recommends a Hold rating [https://seekingalpha.com/symbol/AMAT/ratings/quant-ratings].
* Consensus EPS Estimates: $2.67
* Consensus Revenue Estimates: $7.68B
* Earnings Insight: AMAT has beaten EPS and revenue estimates in 8 straight quarters, missing revenue expectations only once in that span.
ALSO REPORTING: Virgin Galactic Holdings (SPCE [https://seekingalpha.com/symbol/SPCE]), Workhorse Group (WKHS [https://seekingalpha.com/symbol/WKHS]), Canadian Solar (CSIQ [https://seekingalpha.com/symbol/CSIQ]), Vuzix (VUZI [https://seekingalpha.com/symbol/VUZI]), Co-Diagnostics (CODX [https://seekingalpha.com/symbol/CODX]), Canada Goose Holdings (GOOS [https://seekingalpha.com/symbol/GOOS]), Intuitive Machines (LUNR [https://seekingalpha.com/symbol/LUNR]), YETI Holdings (YETI [https://seekingalpha.com/symbol/YETI]), Karyopharm Therapeutics (KPTI [https://seekingalpha.com/symbol/KPTI]), Nu Holdings (NU [https://seekingalpha.com/symbol/NU]), and more.
FRIDAY, MAY 15
The week wraps up on a lighter note, with only a handful of earnings scheduled for Friday's pre-market session. Notable names include Sachem Capital (SACH [https://seekingalpha.com/symbol/SACH]), PAVmed (PAVM [https://seekingalpha.com/symbol/PAVM]), H World Group (HTHT [https://seekingalpha.com/symbol/HTHT]), and more.
MORE ON RELATED STOCKS:
* Cisco Q3 Earnings Preview: Margin Focus As Shares Trade Near Highs [https://seekingalpha.com/article/4899260-cisco-q3-earnings-preview-margin-focus-as-shares-trade-near-highs]
* JD.com: Logistics, AI, And Marketplace Growth Could Drive A Re-Rating [https://seekingalpha.com/article/4897710-jdcom-logistics-ai-and-marketplace-growth-could-drive-a-re-rating]
* Alibaba's AI Engine Is Powering A Still Undervalued Comeback [https://seekingalpha.com/article/4894312-alibabas-ai-engine-is-powering-a-still-undervalued-comeback]
* US said to suspect Nvidia chips smuggled to Alibaba via Thailand, Bloomberg reports [https://seekingalpha.com/news/4589535-us-said-to-suspect-nvidia-chips-smuggled-to-alibaba-via-thailand-bloomberg-reports]
* Kimi chatbot developer Moonshot AI reaches $20B valuation in Meituan-led funding round [https://seekingalpha.com/news/4587927-kimi-chatbot-developer-moonshot-ai-reaches-20b-valuation-in-meituan-led-funding-round]
- WAT Q1 Earnings Beat Estimates, BD Acquisition Aids Revenues
May 7, 2026
Waters WAT delivered first-quarter 2026 adjusted earnings of $2.70 per share, up 20% year over year and beating the Zacks Consensus Estimate by 16.9%. Revenues jumped 91.5% from the year-ago quarter to $1.27 billion and topped the consensus mark of $1.20 billion by 5.2%.
The quarter reflected double-digit organic constant currency (cc) revenue growth of 11%, supported by strength across instruments, chemistry and service, alongside an early contribution from the recently acquired BD Biosciences and Diagnostic Solutions businesses.
WAT’s Organic Engine Stayed in High Gear
Organic revenues increased 13% on a reported basis and 11% at cc, with management noting that orders again outpaced sales. The Analytical Sciences Division rose 12% in cc, led by 8% instrument growth, 13% chemistry growth and 14% service growth.
End-market momentum leaned heavily toward pharma, where the company highlighted mid -teens growth supported by instrument replacement activity and idiosyncratic demand drivers such as GLP-1 manufacturing volume and PFAS testing applications. Academic and government demand also improved, aided by a revitalized high-resolution mass spec portfolio.
Waters Corporation Price, Consensus and EPS Surprise
Waters Corporation price-consensus-eps-surprise-chart | Waters Corporation Quote
Waters Sees Early Execution Wins in Newly Acquired Units
Less than 90 days after closing the Feb. 9 transaction, Waters said newly acquired Biosciences and Diagnostic Solutions generated $520 million of owned-period revenue, exceeding guidance by $40 million. Leadership attributed the upside to a 180-day growth plan emphasizing tighter funnel discipline, higher field activity and faster decision-making.
Pricing discipline and contract compliance are also emerging levers. Management noted it is establishing two deal desks, deploying Waters’ pricing expertise and reviewing reagent rental contracts, identifying roughly 700 out of 1,600 U.S. Diagnostic Solutions contracts as out of compliance, representing a double-digit million-dollar annual shortfall opportunity.
WAT’s Divisions Showed Broad-Based Momentum
Analytical Sciences (former Waters division, excluding the Clinical Business unit) posted $607 million of revenue compared with $534 million in the year-ago quarter. The Biosciences division (formerly known as BD Biosciences) contributed $232 million during the owned period, with Flow Research and Flow Clinical each growing 7% year over year on an estimated as-reported basis. Reagents grew at a low double-digit rate, while instruments remained pressured by U.S. academic trends and China-related constraints.
Advanced Diagnostics delivered $349 million of revenue, combining Diagnostic Solutions of $288 million for the owned period and the Clinical Business Unit at $61 million for the reported quarter (compared with $53 million in the year-ago quarter). The Advanced Diagnostics Division comprises the former BD Diagnostic Solutions business and the Clinical Business unit previously reported within the Waters Division.
Microbiology revenues totaled $203 million for the period and were weighed down by weak respiratory testing tied to a soft flu season.
Materials Sciences (formerly known as TA Division) added $79 million (compared with $75 million in the year-ago quarter), driven by strength in batteries, electronics testing and aerospace, partly offset by softness in core industrial applications.
Story Continues
Waters’ Profitability Improved as Operating Discipline Held
Adjusted gross margin expanded to 54.7%, and adjusted operating margin reached 23.6% (contracted from 25.5% reported in the year-ago quarter), reflecting better-than-expected margin performance before the bulk of cost synergies begin flowing through later in the year.
In the first quarter of 2026, non-GAAP selling and administrative expenses were $299 million, up 76% year over year. Research and development expenses of $95 million, up 106.5% year over year.
WAT’s Balance Sheet Details
As of April 4, 2026, cash and cash equivalents were $462 million, down from $588 million as of Dec. 31, 2025.
Free cash flow was a $42 million outlay, affected by deal-related transaction costs and the timing of net cash settlement with BD.
WAT Raises 2026 Guidance With Synergies in View
Reflecting the strong start, WAT raised 2026 organic cc revenue growth guidance to 6.5%-8%. The company lifted adjusted earnings guidance to $14.40-$14.60 per share. The company now expects acquired businesses to contribute approximately $3.035 billion of reported revenue in 2026, while total reported revenue is projected at $6.405-$6.455 billion.
For the second quarter of 2026, management expects total reported revenue of $1.616-$1.631 billion and adjusted earnings of $2.95-$3.05 per share.
Waters reiterated that it remains on track for $55 million of cost synergies and $50 million of revenue synergies in 2026, driven by cross-selling, instrument replacement, service plan attachment and e-commerce initiatives.
Zacks Rank & Stocks to Consider
Currently, Waters carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader Zacks Medical sector that are set to report their quarterly results are Accendra Health ACH, Agenus AGEN and Altimmune ALT. Accendra Health and Altimmune carry a Zacks Rank #2 (Buy) each at present, while Agenus sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Altimmune is set to report its quarterly results on May 13, while both Accendra Health and Agenus are set to report their quarterly results on May 13. Year to date, shares of Accendra Health and Agenus have returned 38.6% and 18.8%, respectively, while Altimmune has dropped 15%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Accendra Health, Inc. (ACH) : Free Stock Analysis Report
Waters Corporation (WAT) : Free Stock Analysis Report
Altimmune, Inc. (ALT) : Free Stock Analysis Report
Agenus Inc. (AGEN) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
May 6, 2026
GAITHERSBURG, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its first quarter 2026 financial results on Wednesday, May 13, 2026.
Altimmune management will host a conference call at 8:30 a.m. ET on May 13 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors.
Participants who would like to join the call may register here to receive dial-in numbers and a unique PIN. A replay will be available on the Investor Relations website shortly after the call for up to three months.
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X
Investor Contact:
Luis Sanay, CFA
Vice President, Investor Relations
ir@altimmune.com
Media Contact:
Real Chemistry
altimmune@realchemistry.com
- Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
May 6, 2026 · globenewswire.com
GAITHERSBURG, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its first quarter 2026 financial results on Wednesday, May 13, 2026.
- ALTIMMUNE TO REPORT FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON MAY 13, 2026
May 6, 2026
GAITHERSBURG, MD., MAY 06, 2026 (GLOBE NEWSWIRE) -- ALTIMMUNE, INC. (NASDAQ: ALT), A LATE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING PEMVIDUTIDE TO ADDRESS SERIOUS LIVER DISEASES, TODAY ANNOUNCED THAT IT WILL REPORT ITS FIRST QUARTER 2026 FINANCIAL RESULTS ON WEDNESDAY, MAY 13, 2026.
- AI Financial Corporation (Formerly ALT5 Sigma) Begins Trading Under New Nasdaq Ticker Symbol 'AIFC'
Apr 29, 2026 · accessnewswire.com
Ticker Change Reflects the Company's Continued Evolution Across Payments, Tokenization and AI-Driven Infrastructure LAS VEGAS, NV / ACCESS Newswire / April 29, 2026 / AI Financial Corporation (NASDAQ:AIFC)(FRA:5AR1) ("AiFi" or the "Company"), formerly ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech company providing blockchain-powered payment, trading, and settlement infrastructure for digital assets, today announced that its common stock will begin trading under its new corporate name and Nasdaq ticker symbol, AIFC, effective at the open of market trading today, Wednesday, April 29, 2026. The Company's common stock ceased trading under the ticker symbol ALTS following after-market trading on Tuesday, April 28, 2026, and now trades under the new ticker symbol AIFC.
- AI FINANCIAL CORPORATION (FORMERLY ALT5 SIGMA) BEGINS TRADING UNDER NEW NASDAQ TICKER SYMBOL 'AIFC'
Apr 29, 2026
TICKER CHANGE REFLECTS THE COMPANY'S CONTINUED EVOLUTION ACROSS PAYMENTS, TOKENIZATION AND AI-DRIVEN INFRASTRUCTURE LAS VEGAS, NV / ACCESS NEWSWIRE / APRIL 29, 2026 / AI FINANCIAL CORPORATION (NASDAQ:AIFC)(FRA:5AR1) ("AIFI" OR THE "COMPANY"), FORMERLY ALT5 SIGMA CORPORATION (NASDAQ:ALTS), A FINTECH COMPANY PROVIDING BLOCKCHAIN-POWERED PAYMENT, TRADING, AND SETTLEMENT INFRASTRUCTURE FOR DIGITAL ASSETS, TODAY ANNOUNCED THAT ITS COMMON STOCK WILL BEGIN TRADING UNDER ITS NEW CORPORATE NAME AND NASDAQ TICKER SYMBOL, AIFC, EFFECTIVE AT THE OPEN OF MARKET TRADING TODAY, WEDNESDAY, APRIL 29, 2026. THE COMPANY'S COMMON STOCK CEASED TRADING UNDER THE TICKER SYMBOL ALTS FOLLOWING AFTER-MARKET TRADING ON TUESDAY, APRIL 28, 2026, AND NOW TRADES UNDER THE NEW TICKER SYMBOL AIFC.
- Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities
Apr 27, 2026 · globenewswire.com
$225 million funded at closing, with an additional $225 million warrant tranche Financing funds operations through anticipated Phase 3 MASH 52-week data readout Financing was led by Deep Track Capital, with participation from TCGX, Viking Global Investors, RA Capital Management, and other new and existing investors GAITHERSBURG, Md., April 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced the closing of its previously announced underwritten public offering consisting of (i) 64,250,000 shares of its common stock and 64,250,000 accompanying common stock warrants to purchase shares of common stock or pre-funded warrants in lieu thereof and (ii) in lieu of common stock, to certain investors that so choose, pre-funded warrants to purchase an aggregate of up to 10,750,000 shares of its common stock and 10,750,000 accompanying common stock warrants to purchase shares of common stock or pre-funded warrants in lieu thereof, each at an exercise price of $0.001 per pre-funded warrant.
- ALTIMMUNE ANNOUNCES CLOSING OF $225 MILLION OVERSUBSCRIBED PUBLIC OFFERING OF SECURITIES
Apr 27, 2026
$225 MILLION FUNDED AT CLOSING, WITH AN ADDITIONAL $225 MILLION WARRANT TRANCHE FINANCING FUNDS OPERATIONS THROUGH ANTICIPATED PHASE 3 MASH 52-WEEK DATA READOUT FINANCING WAS LED BY DEEP TRACK CAPITAL, WITH PARTICIPATION FROM TCGX, VIKING GLOBAL INVESTORS, RA CAPITAL MANAGEMENT, AND OTHER NEW AND EXISTING INVESTORS GAITHERSBURG, MD., APRIL 27, 2026 (GLOBE NEWSWIRE) -- ALTIMMUNE, INC. (NASDAQ: ALT), A LATE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING PEMVIDUTIDE TO ADDRESS SERIOUS LIVER DISEASES, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING CONSISTING OF (I) 64,250,000 SHARES OF ITS COMMON STOCK AND 64,250,000 ACCOMPANYING COMMON STOCK WARRANTS TO PURCHASE SHARES OF COMMON STOCK OR PRE-FUNDED WARRANTS IN LIEU THEREOF AND (II) IN LIEU OF COMMON STOCK, TO CERTAIN INVESTORS THAT SO CHOOSE, PRE-FUNDED WARRANTS TO PURCHASE AN AGGREGATE OF UP TO 10,750,000 SHARES OF ITS COMMON STOCK AND 10,750,000 ACCOMPANYING COMMON STOCK WARRANTS TO PURCHASE SHARES OF COMMON STOCK OR PRE-FUNDED WARRANTS IN LIEU THEREOF, EACH AT AN EXERCISE PRICE OF $0.001 PER PRE-FUNDED WARRANT.
- Altimmune, Inc. (NASDAQ:ALT) Receives Average Recommendation of “Moderate Buy” from Analysts
Apr 27, 2026 · defenseworld.net
Altimmune, Inc. (NASDAQ: ALT - Get Free Report) has been given an average rating of "Moderate Buy" by the ten analysts that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have issued a buy recommendation on the company.
